isr20231117_8k.htm
false 0000728387 0000728387 2023-12-05 2023-12-05
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 5, 2023
 
 
Perspective Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware
001-33407
41-1458152
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
2401 Elliott Avenue, Suite 320, Seattle, Washington
  
98121
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (206) 676-0900
 
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
  
CATX
  
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 1.01.
Entry into a Material Definitive Agreement.
 
On December 5, 2023, Isoray Medical, Inc. (“Medical”), a wholly-owned subsidiary of Perspective Therapeutics, Inc. (the “Company”), entered into a supply contract (the “2024 Agreement”) with Joint Stock Company «Isotope», a Russian company (“JSC Isotope”). Pursuant to the 2024 Agreement, Medical will purchase Cesium-131 manufactured by Joint Stock Company ‹‹Institute of Nuclear Materials›› and sold by JSC Isotope, at the quality standards, volume, and pricing indicated in the 2024 Agreement. The 2024 Agreement is dated December 5, 2023 for shipments beginning January 1, 2024, and terminates March 31, 2025. Medical and JSC Isotope previously entered into separate supply contracts, dated November 28, 2022, which are superseded by the 2024 Agreement. The 2024 Agreement has a new price and the Company will make purchases beginning January 1, 2024 under the 2024 Agreement.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d)
Exhibits
 
Exhibit
No.
  
Description
10.1*
   2024 Supply Contract, executed December 5, 2023, between Isoray Medical, Inc., and Joint Stock Company «Isotope».
     
104
  
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
     
* Certain portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PERSPECTIVE THERAPEUTICS, INC.
Date: December 6, 2023 
By:
/s/ Johan (Thijs) Spoor
Johan (Thijs) Spoor
Chief Executive Officer